首页 › 基金 › EVENTIDE ASSET MANAGEMENT, LLC › PCVX
EVENTIDE ASSET MANAGEMENT, LLC 对 PCVX 的持仓历史
VAXCYTE INC · 医疗保健
EVENTIDE ASSET MANAGEMENT, LLC 在 Q3 2026 的 13F 申报中披露持有 PCVX(VAXCYTE INC)1,380,144 股,市值约 US$78.5M,约占其申报组合的 1.10%,在其申报持仓中市值排名第 19 位。 EVENTIDE ASSET MANAGEMENT, LLC 最近 13 个申报季度中有 13 个季度披露了 PCVX 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR
EVENTIDE ASSET MANAGEMENT, LLC 对 PCVX 的持仓演变
EVENTIDE ASSET MANAGEMENT, LLC 于 Q3 2023 首次披露 PCVX 持仓:393,000 股(约 US$20.0M)。 该持仓在 Q2 2026 达到峰值 1,380,219 股,市值约 US$80.2M。 在 13 次申报中,EVENTIDE ASSET MANAGEMENT, LLC 7 次增持、2 次减持、3 次保持不变。 最近一期申报(Q3 2026)显示持股 1,380,144 股、市值约 US$78.5M。 持仓曾出现大幅变动:Q2 2025 增持约 80% (随后一个季度股价上涨 11%)、Q3 2025 减持约 55% (随后一个季度股价上涨 28%)、Q4 2025 增持约 142% (随后一个季度股价上涨 26%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 393.00K | $20.04M | 新进 |
| Q4 2023 | 607.21K | $38.13M | 增持 |
| Q1 2024 | 657.21K | $44.89M | 增持 |
| Q2 2024 | 739.15K | $55.81M | 增持 |
| Q3 2024 | 383.45K | $43.82M | 减持 |
| Q4 2024 | 383.45K | $31.39M | 持有 |
| Q1 2025 | 470.23K | $17.80M | 增持 |
| Q2 2025 | 848.14K | $27.57M | 增持 |
| Q3 2025 | 379.33K | $13.66M | 减持 |
| Q4 2025 | 917.12K | $42.31M | 增持 |
| Q1 2026 | 1.37M | $79.84M | 增持 |
| Q2 2026 | 1.38M | $80.23M | 持有 |
| Q3 2026 | 1.38M | $78.53M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 PCVX 与 13F 数据
PCVX(VAXCYTE INC)属于医疗保健行业。我们追踪的基金中还有 32 只申报持有 PCVX,申报仓位最大的包括:Jupiter Topco LLC (US$1.04B), 骏利亨德森集团 (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 PCVX 的基金
- Jupiter Topco LLC 17.97M 股 · $1.04B · Q2 2026
- 骏利亨德森集团 16.58M 股 · $960.23M · Q1 2026
- T. Rowe Price Investment Management, Inc. 12.21M 股 · $709.62M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 11.47M 股 · $667.02M · Q2 2026
- Deep Track Capital, LP 4.30M 股 · $249.96M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 3.28M 股 · $186.60M · Q3 2026
- Kynam Capital Management, LP 2.92M 股 · $169.88M · Q2 2026
- Caligan Partners LP 2.19M 股 · $127.23M · Q2 2026
- Paradigm Biocapital Advisors LP 2.13M 股 · $123.69M · Q2 2026
- Bellevue Group AG 1.97M 股 · $114.63M · Q2 2026
- Maverick 资本 1.61M 股 · $93.78M · Q2 2026
- MAVERICK CAPITAL LTD 1.61M 股 · $93.78M · Q2 2026
更多关于 EVENTIDE ASSET MANAGEMENT, LLC
常见问题
How long has EVENTIDE ASSET MANAGEMENT, LLC held PCVX?
EVENTIDE ASSET MANAGEMENT, LLC has disclosed PCVX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is EVENTIDE ASSET MANAGEMENT, LLC's current position in PCVX?
As of Q3 2026, EVENTIDE ASSET MANAGEMENT, LLC holds 1.38M shares of PCVX (VAXCYTE INC), valued at $78.53M, representing 1.10% of its reported portfolio and ranking #19.
Has EVENTIDE ASSET MANAGEMENT, LLC been buying or selling PCVX?
In the latest 13F filing (Q3 2026), EVENTIDE ASSET MANAGEMENT, LLC held unchanged its position in PCVX. The position peaked in Q2 2026 at 1.38M shares.
Which other funds hold PCVX?
Other major institutional holders of PCVX include Jupiter Topco LLC, 骏利亨德森集团, T. Rowe Price Investment Management, Inc., among 32 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.